An Open, Exploratory Clinical Study to Assess Safety and Efficacy of BCMA-CD3 Bispecific Antibody CM336 in the Treatment of Primary Immune Thrombocytopenia
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs CM 336 (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 04 Feb 2025 New trial record